Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Sana Al Sukhun, Sarah Temin, Carlos H Barrios, Nicoleta Zenovia Antone, Yanin Chavarri Guerra, Mariana Chavez-MacGregor, Rakesh Chopra, Michael A Danso, Henry Leonidas Gomez, N'Da Marcelin Homian, Alaa Kandil, Benda Kithaka, Bogda Koczwara, Beverly Moy, Gertrude Nakigudde, Fernando Enrique Petracci, Hope S Rugo, Nagi S El Saghir, Banu K Arun
PURPOSE: To guide clinicians and policymakers in three global resource-constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting-guideline recommended treatment is unavailable. METHODS: A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes. RESULTS: Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement...
January 2024: JCO global oncology
#2
JOURNAL ARTICLE
Marina Elena Cazzaniga, Antonio Ciaccio, Romano Danesi, Francois P Duhoux, Corrado Girmenia, Kalhil Zaman, Henrik Lindman, Fabrizio Luppi, Dimitrios Mavroudis, Ida Paris, Ayodele Olubukola, Ahmed Samreen, Christian Schem, Christian Singer, Anton Snegovoy
The personalization of therapies in breast cancer has favoured the introduction of new molecular-targeted therapies into clinical practice. Among them, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have acquired increasing importance, with the approval in recent years of palbociclib, ribociclib, and abemaciclib in combination with endocrine therapy. Currently, no guidelines are available to monitor and manage potential long-term toxicities associated with the use of these drugs. A multidisciplinary panel of European oncologists, was supported by a pharmacologist, a hematologist, a hepatologist and a pulmonologist to discuss the management of long-term toxicities, based on the literature review and their clinical experience...
2023: Frontiers in Oncology
#3
JOURNAL ARTICLE
Eva Juengel, Jochen Rutz, Moritz Meiborg, Sascha D Markowitsch, Sebastian Maxeiner, Timothy Grein, Anita Thomas, Felix K-H Chun, Axel Haferkamp, Igor Tsaur, Olesya Vakhrusheva, Roman A Blaheta
Extracts of European mistletoe ( Viscum album ) are popular as a complementary treatment for patients with many different cancer types. However, whether these extracts actually block bladder cancer progression remains unknown. The influence of different mistletoe extracts on bladder cancer cell growth and proliferation was investigated by exposing RT112, UMUC3, and TCCSup cells to mistletoe from hawthorn ( Crataegi ), lime trees ( Tiliae ), willow trees ( Salicis ), or poplar trees ( Populi ). The tumor cell growth and proliferation, apoptosis induction, and cell cycle progression were then evaluated...
October 4, 2023: Cancers
#4
REVIEW
Federica Villa, Alessandra Crippa, Davide Pelizzoni, Alessandra Ardizzoia, Giulia Scartabellati, Cristina Corbetta, Eleonora Cipriani, Marialuisa Lavitrano, Antonio Ardizzoia
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review the cellular mechanisms underlying the resistance to CDK4/6is, as well as treatment strategies and the clinical data about the efficacy of subsequent treatments after CDK4/6is-based therapy. In the first part, this review mainly discusses cell-cycle-specific and cell-cycle-non-specific resistance to CDK4/6is, with a focus on early and late progression...
September 22, 2023: International Journal of Molecular Sciences
#5
JOURNAL ARTICLE
Jürgen Geisler, Peeter Karihtala, Malgorzata Tuxen, Antonis Valachis, Barbro Holm
BACKGROUND: This Delphi study aimed to assess current perspectives on hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) advanced breast cancer (aBC) treatment strategies across the Nordics, and to establish where consensus exists across the Nordics on HR+/HER2- aBC treatment. MATERIAL AND METHODS: A modified, three-round Delphi method was followed. A steering committee was appointed for study coordination, panellist selection, and questionnaire development...
September 15, 2023: Acta Oncologica
#6
JOURNAL ARTICLE
Marcin Kubeczko, Michał Jarząb, Dorota Gabryś, Aleksandra Krzywon, Alexander J Cortez, Amy J Xu
BACKGROUND AND PURPOSE: The addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has led to practice-changing improvements in overall survival. However, there are conflicting data concerning the safety of CDK4/6i combination with radiotherapy, and no consensus guidelines exist to guide practice. We conducted a meta-analysis to assess the safety and feasibility of CDK4/6i treatment with radiotherapy...
October 2023: Radiotherapy and Oncology
#7
JOURNAL ARTICLE
L Bender, C Pflumio, P Trensz, L Pierard, M Kalish, C Fischbach, T Petit
BACKGROUND: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer. The optimal subsequent treatment after CDK4/6 inhibitor remain unclear. As recommended by standard guidelines, capecitabine, an oral chemotherapy is a therapeutic option in endocrine resistant metastatic breast cancer. The objective of this study was to evaluate capecitabine efficacy after disease progression under combination of ET and CDK4/6 inhibitor in a hormone receptor positive metastatic breast cancer population...
June 25, 2023: Cancer Treatment and Research Communications
#8
JOURNAL ARTICLE
Elaine Goh, Sylvie Labelle, Angela Chan
BACKGROUND: The introduction of CDK 4/6 inhibitors for breast cancer patients has contributed to increased ambulatory patient visits for oncologists. The Medication Assessment by Pharmacist program aims to evaluate the impact of oncology pharmacists performing medication assessment follow-up visits. METHODS: Breast cancer patients on a CDK 4/6 inhibitor deemed suitable by their oncologist for pharmacist assessment could be booked for a pharmacist medication assessment appointment at alternate treatment cycles...
May 31, 2023: Journal of Oncology Pharmacy Practice
#9
RANDOMIZED CONTROLLED TRIAL
Tom Degenhardt, Peter A Fasching, Diana Lüftner, Volkmar Müller, Christoph Thomssen, Christian Schem, Isabell Witzel, Thomas Decker, Hans Tesch, Sherko Kümmel, Christoph Uleer, Rachel Wuerstlein, Oliver Hoffmann, Mathias Warm, Norbert Marschner, Timo Schinköthe, Ronald E Kates, Johannes Schumacher, Burkhard Otremba, Matthias Zaiss, Nadia Harbeck, Marcus Schmidt
BACKGROUND: Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 -) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor (e.g., palbociclib, ribociclib, abemaciclib) to endocrine therapy substantially prolongs progression-free survival and in the case of a CDK 4/6i also overall survival...
May 17, 2023: Trials
#10
JOURNAL ARTICLE
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based)...
February 10, 2023: BMC Cancer
#11
Toshihiko Yoneto, Kenichiro Hasumi, Yuzo Fujii, Nobukazu Takahashi, Natsuki Seki, Takayuki Yoshimoto, Yasutaka Takeda
Background: In recent years, a number of agents possessing novel mechanisms, such as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and PIK3CA inhibitors, have been developed for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor type negative (HER2-) advanced or recurrent breast cancer. As a result, the treatment strategies for advanced or recurrent breast cancer have changed significantly. The combination of CDK 4/6 inhibitors administration and endocrine therapy is now widely used in the treatment of HR+ HER2- recurrent breast cancer with improved outcomes...
October 2022: Translational Cancer Research
#12
EDITORIAL
Amol Akhade, Simon Van Wambeke, Bishal Gyawali
CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All three of these drugs have similar mechanism of action and other pharmacokinetic and pharmaco-dynamic properties and hold equivalent positions in cancer care guidelines. Surprisingly, however, in the adjuvant setting of early breast cancer, two trials of palbociclib have failed to show any benefit while abemaciclib has shown some early benefits in disease-free survival and has received approval for its use in adjuvant setting...
2022: Ecancermedicalscience
#13
REVIEW
Hikmat Abdel-Razeq, Fawzi Abu Rous, Fawzi Abuhijla, Nayef Abdel-Razeq, Sarah Edaily
Breast cancer is the most common cancer diagnosed among women worldwide and more than half are diagnosed above the age of 60 years. Life expectancy is increasing and the number of breast cancer cases diagnosed among older women are expected to increase. Undertreatment, mostly due to unjustifiable fears of advanced-age and associated comorbidities, is commonly practiced in this group of patients who are under-represented in clinical trials and their management is not properly addressed in clinical practice guidelines...
2022: Clinical Interventions in Aging
#14
JOURNAL ARTICLE
Harold J Burstein, Mark R Somerfield, Debra L Barton, Ali Dorris, Lesley J Fallowfield, Dharamvir Jain, Stephen R D Johnston, Larissa A Korde, Jennifer K Litton, Erin R Macrae, Lindsay L Peterson, Praveen Vikas, Rachel L Yung, Hope S Rugo
PURPOSE: To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. METHODS: An Expert Panel conducted a systematic review to identify new, potentially practice-changing data. RESULTS: Fifty-one articles met eligibility criteria and form the evidentiary basis for the recommendations. RECOMMENDATIONS: Alpelisib in combination with endocrine therapy (ET) should be offered to postmenopausal patients, and to male patients, with HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA -mutated, ABC, or MBC following prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor...
December 10, 2021: Journal of Clinical Oncology
#15
REVIEW
Gustavo Werutsky, Tomás Reinert, Mahira Lopes Rosa, Carlos Henrique Barrios
Hormone receptor-positive (HR+ ) human epidermal growth factor receptor-2 negative (HER2- ) tumors represent the most common subtype of metastatic breast cancer (MBC). International guidelines clearly state that endocrine therapy (ET) should be considered the preferred first-line therapy for these patients in the absence of very symptomatic visceral disease or evidence of endocrine resistance. Nonetheless compliance with guidelines significantly vary worldwide for many different reasons. Historically, a substantial proportion of patients with HR+ HER2- MBC have been treated with chemotherapy (CT) in first-line setting, jeopardizing patients' quality of life without a significant benefit in outcome...
April 20, 2021: Clinical Breast Cancer
#16
JOURNAL ARTICLE
Vivian Le, Lixian Zhong, NihaL Narsipur, Elizabeth Hays, Daniel Khuong Tran, Kimberly Rosario, Leslie Wilson
BACKGROUND: The 2015 American Society of Clinical Oncology guidelines recommend first-line treatment of hormone receptor (HR)-positive breast cancer with endocrine therapy plus or minus palbociclib, a selective cyclin-dependent kinase (CDK)4/6 inhibitor. In 2018, the U.S. Food and Drug Administration approved ribociclib, a new orally available selective CDK4/6 inhibitor. While gains in progression-free survival (PFS) and overall survival (OS) from ribociclib are important for clinical and treatment outcomes, trade-offs in adverse events (AEs) and additional costs necessitate cost-effectiveness analysis (CEA) to assist consideration by third-party payer systems, physicians, and patients...
March 2021: Journal of Managed Care & Specialty Pharmacy
#17
REVIEW
Georges El Hachem, Andrea Gombos, Ahmad Awada
INTRODUCTION: The field of metastatic luminal breast cancer (hormone receptor positive, HER-2 negative) is dynamic and evolving, harboring some of the most significant therapeutic advances in medical oncology. Over the last decade, many pivotal trials showed excellent results with drastic improvements in survival as well as the quality of life of metastatic luminal breast cancer patients. AREAS COVERED: The successful inhibition of the cyclinD/cyclin-dependent kinases 4 and 6 (CDK4/6)-retinoblastoma protein (RB) pathway with potent CDK4/6 inhibitors improved the outcome of advanced luminal breast cancers...
January 2021: Expert Review of Anticancer Therapy
#18
JOURNAL ARTICLE
Mariana Brandão, Christian Maurer, Patricia Klarmann Ziegelmann, Noam F Pondé, Arlindo Ferreira, Samuel Martel, Martine Piccart, Evandro de Azambuja, Márcio Debiasi, Matteo Lambertini
BACKGROUND: Several endocrine therapy (ET)-based treatments are available for patients with advanced breast cancer. We assessed the efficacy of different ET-based treatments in patients with hormone receptor-positive/HER2-negative advanced breast cancer with endocrine-sensitive or endocrine-resistant disease. METHODS: We searched Medline and Cochrane Central Register of Controlled Trials up to 15 October 2019 and abstracts from major conferences from 2016 to October 2019...
August 2020: ESMO Open
#19
REVIEW
Neil S Friedman, Lital Shaham, Nehama Sharon, Chani Barlev
Women who present with locally advanced breast cancer that would require a mastectomy are often recommended to undergo chemotherapy prior to surgery in hopes of down-staging the tumor and allowing for breast-conserving surgery. This approach is very effective in women with triple negative and Her2neu positive locally advanced breast cancer, yet the results in ER/PR positive (luminal) breast cancers have been less effective. In post-menopausal women, neoadjuvant hormonal treatment in such cases can cause tumor regression and allow for breast-conserving therapy, in some patients...
May 2020: Harefuah
#20
JOURNAL ARTICLE
Tatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, Tatsuya Toyama, Hiroji Iwata
BACKGROUND: In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer. METHODS: We performed a systematic review of relevant reports from randomized-controlled studies published prior to November 2016 found using medical journal search engines. The main outcomes which we evaluated were progression-free survival (PFS), objective response rate (ORR), disease control rate (CBR), and toxicity...
February 11, 2020: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
